Literature DB >> 22654544

Diarrhea-associated hemolytic uremic syndrome in southern Alberta: A long-term single-centre experience.

Silviu Grisaru1, Julian P Midgley, Lorraine A Hamiwka, Andrew W Wade, Susan M Samuel.   

Abstract

BACKGROUND: Reports of long-term incidence trends of endemic diarrhea-associated hemolytic uremic syndrome (D+HUS) are few and inconclusive.
OBJECTIVE: To define and analyze the incidence and outcomes of D+HUS over a period of approximately 25 years in a highly endemic region of southern Alberta.
METHODS: Annual incidence rates of confirmed cases of D+HUS were compared between two 12-year periods (1980 to 1992 and 1994 to 2006). Differences in therapies used, and some short- and long-term complications observed were also compared between the two periods.
RESULTS: The absolute yearly number of D+HUS cases was highly variable. The comparison between the 1980 to 1992, and 1994 to 2006 periods demonstrated a modest 8.8% decrease in the total number of cases. The population-based average annual incidence rates were not significantly different between the two time periods (3.33 cases versus 2.58 cases per 100,000 population per year, respectively; P=0.30). Only supportive care measures were used in the latter period. A mortality rate of lower than 1% in the latter period was one of the lowest ever reported for a large cohort of D+HUS patients.
CONCLUSION: The present long-term retrospective study of D+HUS in a highly endemic area documented a modest decrease in the absolute number of cases but no difference in the average annual incidence over an extended period of time.

Entities:  

Keywords:  Hemolytic uremic syndrome; Incidence; Outcomes

Year:  2011        PMID: 22654544      PMCID: PMC3328224          DOI: 10.1093/pch/16.6.337

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  17 in total

1.  Association between indicators of cattle density and incidence of paediatric haemolytic-uraemic syndrome (HUS) in children under 15 years of age in France between 1996 and 2001: an ecological study.

Authors:  R Haus-Cheymol; E Espie; D Che; V Vaillant; H DE Valk; J C Desenclos
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

2.  Population-based trends in pediatric hemolytic uremic syndrome in California, 1994-1999: substantial underreporting and public health implications.

Authors:  Kate C Cummings; Janet C Mohle-Boetani; S Benson Werner; Duc J Vugia
Journal:  Am J Epidemiol       Date:  2002-05-15       Impact factor: 4.897

3.  Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Société de Néphrologie Pédiatrique.

Authors:  B Decludt; P Bouvet; P Mariani-Kurkdjian; F Grimont; P A Grimont; B Hubert; C Loirat
Journal:  Epidemiol Infect       Date:  2000-04       Impact factor: 2.451

Review 4.  Treatment options for HUS secondary to Escherichia coli O157:H7.

Authors:  Martin Bitzan
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

5.  Diarrhea-associated hemolytic uremic syndrome.

Authors:  W L Robson; A K Leung; C L Trevenen; R Brant
Journal:  Can Fam Physician       Date:  1993-10       Impact factor: 3.275

6.  A population-based study of hemolytic-uremic syndrome in Oregon, 1979-1982.

Authors:  M F Rogers; G W Rutherford; S R Alexander; J H DiLiberti; L Foster; L B Schonberger; E S Hurwitz
Journal:  Am J Epidemiol       Date:  1986-01       Impact factor: 4.897

7.  Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 states, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-04-11       Impact factor: 17.586

8.  Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre.

Authors:  P C Rowe; E Orrbine; G A Wells; P N McLaine
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

Review 9.  Epidemiology and spectrum of disease of Escherichia coli O157.

Authors:  Theresa J Ochoa; Thomas G Cleary
Journal:  Curr Opin Infect Dis       Date:  2003-06       Impact factor: 4.915

10.  Childhood hemolytic uremic syndrome, United Kingdom and Ireland.

Authors:  Richard M Lynn; Sarah J O'Brien; C Mark Taylor; Goutam K Adak; Henrik Chart; Tom Cheasty; John E Coia; Iain A Gillespie; Mary E Locking; William J Reilly; Henry R Smith; Aoife Waters; Geraldine A Willshaw
Journal:  Emerg Infect Dis       Date:  2005-04       Impact factor: 6.883

View more
  5 in total

Review 1.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

Review 2.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

3.  Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex.

Authors:  Alipio Pinto; Mariana Jacobsen; Patricia A Geoghegan; Adriana Cangelosi; María Laura Cejudo; Carla Tironi-Farinati; Jorge Goldstein
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

Review 4.  Management of hemolytic-uremic syndrome in children.

Authors:  Silviu Grisaru
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-06-12

Review 5.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review.

Authors:  Adrien Joseph; Aurélie Cointe; Patricia Mariani Kurkdjian; Cédric Rafat; Alexandre Hertig
Journal:  Toxins (Basel)       Date:  2020-01-21       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.